Early onset type 2 diabetes, abbreviated EOT2D, is increasingly recognised by clinicians as a distinct and particularly aggressive clinical phenotype. Because it strikes in the third and fourth decades of life, the disease has decades longer to inflict damage on blood vessels, nerves, kidneys and the heart. People diagnosed young experience more rapid deterioration in blood sugar control, develop complications earlier, and face a lower life expectancy than those whose type 2 diabetes appears later in life. As rates of obesity rise across the globe, the number of young adults affected is climbing steeply, making the search for potent, disease-modifying interventions an urgent priority for health systems worldwide.

The biological rationale behind the trial, known as RESET for Remission, rests on the complementary effects of dietary energy restriction and exercise. Low energy diets have previously been shown to drive glucose levels below the diagnostic threshold for type 2 diabetes without the need for medication, a state defined as remission. Adding structured exercise may deliver synergistic advantages: greater cardiorespiratory fitness, preservation of muscle mass during rapid weight loss, enhanced cardiac function, and reduced insulin resistance. The researchers reasoned that a condition as aggressive as early onset type 2 diabetes merits an intervention powerful enough to arrest its swift evolution, and they designed the study to test whether combining the two approaches would outperform usual care.

The trial was a randomised, open-label, blinded endpoint efficacy study conducted across three centres in England and Canada, affiliated with the University of Leicester, McGill University in Montreal, and the University of Alberta in Edmonton. It enrolled adults aged 18 to 45 with early onset type 2 diabetes and obesity who were not taking insulin therapy. Between September 24, 2021 and June 6, 2025, a total of 96 participants were randomised, 40 in the United Kingdom and 56 in Canada. The intervention group comprised 24 women and 26 men, while the control group had 21 women and 25 men. The mean age of participants was 38 years and the mean body mass index was 35.2 kilograms per square metre. Notably, 86 participants, or 90 percent, attended final assessments, a retention rate that strengthens confidence in the findings.

The intervention itself was demanding but carefully structured. Participants stopped all glucose-lowering and blood pressure-lowering medication, in the absence of albuminuria, as they began an 800 to 900 kilocalorie per day diet providing 30 percent of energy from protein, 50 percent from carbohydrate and 20 percent from fat. They were encouraged to drink at least two litres of calorie-free fluid daily and were given a fibre-based laxative to use as required. The first two weeks consisted of total meal replacement using Optifast. From weeks 3 to 12, the same caloric intake continued with more variety, using Optifast in the United Kingdom and ProtiDiet in Canada, alongside one food-based meal per day supplying 60 to 90 grams of protein from all sources combined, one portion of fruit and two portions of non-starchy vegetables.

Exercise ran in parallel with the dietary phase. During weeks 1 to 12, participants completed twice-weekly supervised sessions covering both aerobic and resistance training, plus one weekly independent exercise session. From weeks 13 to 24, they transitioned to a weight-maintenance diet while continuing independent exercise. The primary outcome was remission at 24 weeks, defined as a glycated haemoglobin level below 6.5 percent, or 48 millimoles per mole, together with the absence of glucose-lowering medication for at least 12 weeks. The primary efficacy and harms analysis included all randomised individuals, with a conservative assumption that missing data meant no remission. Secondary endpoints captured cardiorespiratory fitness, body composition and cardiac structure.

The results were striking across multiple dimensions. Intervention participants, who averaged 100.7 kilograms at baseline, lost a mean of 8.4 kilograms by week 24, reaching an average weight of 92.3 kilograms. Control participants, who averaged 103.2 kilograms at the start, lost only 1.2 kilograms, ending at a mean of 102.0 kilograms. After statistical adjustment, the analysis showed that intervention participants lost 7.5 kilograms more than controls, including 6.6 additional kilograms of fat mass. Critically, the trial demonstrated that fat-free mass and muscle preservation are achievable even during rapid weight loss, a finding the authors attribute to the resistance training component that deliberately targeted muscle during the intensive dietary phase.

Safety data were reassuring. Remission was achieved without any severe adverse events. Most participants in the intervention group, 43 of 50, experienced at least one adverse event, compared with 6 of 46 in the control group, but these were mainly the familiar early effects of very low energy diets, such as constipation, headache, dizziness and fatigue, all of which resolved. This profile mirrors what has been reported in previous meal replacement trials and suggests that, under appropriate supervision, the intervention is tolerable for the majority of young adults willing to undertake it.

The authors emphasised the breadth of the benefits beyond blood sugar control. In their summary of the RESET for Remission findings, they report that combining structured aerobic and resistance exercise with a low-calorie diet produced high remission rates, induced fat loss while preserving muscle mass, improved muscle quality and function, enhanced cardiovascular health, and led to meaningful improvements in patient-reported outcomes. They noted that their remission rates sit at the upper end of those previously reported in the literature for trials of similar duration, and that this is the first time such effects have been demonstrated in a multi-ethnic population with early onset type 2 diabetes through a combined low energy diet and structured exercise intervention.

The researchers are candid about the challenges that remain. All weight loss programmes, including low energy diets used for type 2 diabetes remission, are typically followed by a period of partial or full weight regain for most people. Because weight loss driven by lower energy intake alone reduces both fat and fat-free mass, and there is some evidence that weight regain may preferentially restore fat over fat-free mass, there is a long-term risk of net muscle loss and increased sarcopenia. Preserving muscle during remission-oriented weight loss, they argue, may have important implications for long-term metabolic health, physical function and disease trajectory, though this requires confirmation in longer-term studies. They also highlight that their approach may be particularly valuable for those seeking or with potential for pregnancy, a group in which medication options are limited. As the global prevalence of early onset type 2 diabetes continues to rise, the team concludes that the findings present an opportunity to re-evaluate treatment paradigms and support scalable implementation of integrated dietary and exercise interventions, pending further evaluation in real-world settings.

Subject of Research: Remission of early onset type 2 diabetes through a combined low energy diet and structured exercise intervention

Article Title: Study shows low energy diet combined with structured exercise reverses early onset type 2 diabetes in half of participants

Article References: Study shows low energy diet combined with structured exercise reverses early onset type 2 diabetes in half of participants. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 2 diabetes, diabetes remission, low energy diet, structured exercise, early onset diabetes, randomised controlled trial, weight loss, resistance training, McGill University, University of Leicester, EASD, The Lancet Regional Health Americas

The pharmacological logic is elegant. Amylin naturally suppresses postprandial glucose excursions and curbs appetite through actions in brainstem regions such as the area postrema and the nucleus tractus solitarius, while also slowing gastric emptying. Amylin agonism first entered the clinic with pramlintide, a synthetic amylin analogue approved for both type 1 and type 2 diabetes, but its modest effects on glycated haemoglobin (HbA1c) and body weight, together with demanding dosing schedules, limited its impact. The new agents overcome these barriers through long-acting engineering. Cagrilintide is a long-lasting amylin analogue paired in CagriSema with semaglutide, a GLP-1 receptor agonist. Zenagamtide goes further, folding both the amylin and GLP-1 receptor pharmacophores into a single unimolecular co-agonist that can be given by injection or, with the aid of the absorption enhancer SNAC, as an oral tablet. Eloralintide, by contrast, is a long-acting dual amylin and calcitonin receptor agonist acting predominantly at the amylin type 1 receptor, with albumin binding allowing weekly dosing and a pharmacokinetic half-life of roughly 15 days.

Zenagamtide’s oral data read like a teaser for what injection can achieve. In a phase 1 randomised, double-blind, placebo-controlled trial, oral zenagamtide over 85 days produced weight loss of up to 13.1 percent at the 250 mg dose, corresponding to 11.9 kg, alongside reductions in BMI of about 4.1 kg/m2, waist circumference decreases of up to 9.5 cm, systolic blood pressure falls of 3 to 9 mmHg, and small favourable shifts in glucose and lipids. The drug was absorbed rapidly, reaching maximum levels within roughly 42 minutes, and had a terminal half-life between 92 and 100 hours, explaining the durable effect. Adverse events were predominantly mild-to-moderate gastrointestinal complaints concentrated at higher doses, and doses above 25 mg were judged intolerable. One serious event, a case of diabetic ketoacidosis, was subsequently traced to newly diagnosed type 1 diabetes in the participant rather than to the drug itself.

The subcutaneous formulation is where zenagamtide becomes genuinely startling. In a phase 1b/2a study lasting 36 weeks, the highest dose of 60 mg achieved a mean body weight reduction of 24.3 percent, an estimated treatment difference of 23.2 percent against placebo, with HbA1c falling by 0.6 percent and fasting plasma glucose by 0.8 mmol/L at the top dose. Dose escalation to 60 mg proved safe and tolerable, with nausea, vomiting, diarrhoea and reduced appetite as the main complaints, no clinically meaningful drops in ionised calcium, and no QT prolongation exceeding 60 ms. That magnitude of weight loss, approaching the results of bariatric surgery, places an injectable co-agonist among the most effective pharmacological anti-obesity therapies ever tested.

Eloralintide tells a different story, one of pure amylin agonism. In a 48-week phase 2, double-blind, randomised, placebo-controlled trial, the 9 mg dose produced a mean weight reduction of 20.1 percent, or 21.3 kg, with all active doses from 1 mg upward significantly outperforming placebo. BMI fell by up to 7.8 kg/m2 and waist circumference by up to 17.1 cm. Notably, body composition analysis revealed a 3:1 fat-to-lean mass loss ratio, a favourable profile for a class often criticised for stripping muscle along with fat. The adverse event pattern was also distinctive: rather than the nausea and vomiting typical of GLP-1 drugs, fatigue, headache and appetite loss dominated, injection-site reactions were reported in a dose-dependent minority, and no cases of pancreatitis or cholecystitis occurred. Pulse rate actually fell by up to 14.4 beats per minute in early studies, the opposite of the heart rate increase seen with GLP-1 receptor agonists, and gastric emptying effects were negligible.

CagriSema, the furthest along in development, has now delivered phase 3 data in both obesity and diabetes. In a 68-week trial in people with overweight or obesity, 32.1 percent of whom had prediabetes, the combination reduced body weight by 20.4 percent under the treatment-policy estimand and by 22.7 percent, an absolute loss of 26.6 kg, under the trial-product estimand, decisively outperforming either semaglutide alone (14.9 percent) or cagrilintide alone (11.5 percent). Nearly one in five participants lost 30 percent or more of their body weight. Fat mass fell by 17.0 kg against 8.4 kg of lean mass, waist circumference shrank by 13.4 cm more than placebo, systolic blood pressure dropped by 9.9 mmHg, and 87.7 percent of participants with prediabetes reverted to normoglycaemia. Quality-of-life instruments measuring the impact of weight on daily living improved significantly.

In type 2 diabetes, CagriSema is currently the best-characterised amylin-based agent, and its results are remarkable across the disease spectrum. In people with overweight or obesity and T2DM, 68 weeks of treatment cut HbA1c by 1.4 percent and weight by up to 15.7 percent, with time in glycaemic range nearly doubling from 43.6 to 86.8 percent on continuous glucose monitoring. In the REIMAGINE 1 trial of treatment-naïve patients, HbA1c fell by 1.8 percent with the 2.4 mg dose, and strikingly, roughly one in two participants achieved formal T2DM remission, defined as HbA1c below 6.5 percent without any antidiabetic medication after a 12-week off-treatment period. In REIMAGINE 3, patients already on basal insulin achieved HbA1c reductions of up to 2.33 percent while actually reducing their daily insulin requirement by about 20 units, and in REIMAGINE 2 the combination beat both semaglutide and cagrilintide head-to-head on glycaemic control while producing 14.2 percent weight loss. A composite outcome of HbA1c at or below 6.5 percent plus at least 10 percent weight loss was achieved by 57.3 percent of patients on the high dose versus zero on semaglutide alone.

Safety across the class appears broadly acceptable and largely consistent with established incretin therapy for the GLP-1-containing agents. Mild-to-moderate gastrointestinal events, chiefly nausea, vomiting, diarrhoea and constipation, peak during dose escalation and remain the leading cause of discontinuation, affecting roughly 72 to 80 percent of CagriSema users in some trials against 34 to 40 percent on placebo. Hypoglycaemia was uncommon and mostly attributable to concomitant sulfonylurea use. A handful of acute pancreatitis cases and injection-site reactions were recorded in the large diabetes trials, and malignancy rates were similar to placebo. Transient, subclinical dips in ionised calcium were seen with zenagamtide, a pharmacological echo of its calcitonin-family receptor activity. Eloralintide’s cleaner gastrointestinal profile, combined with its heart-rate-lowering effect, raises the prospect of an option for patients who cannot tolerate GLP-1-based regimens, although its fatigue and appetite-loss signals, and rare mood-related events that resolved within days of discontinuation, warrant continued scrutiny.

The pipeline behind these three drugs is now extraordinarily dense. Zenagamtide is being tested across the AMAZE programme in T2DM, weight maintenance, knee osteoarthritis, obstructive sleep apnoea, heart failure with preserved and mildly reduced ejection fraction, and in hepatic and renal impairment, alongside an oral formulation being evaluated in Japanese and Chinese populations. Eloralintide’s ENLIGHTEN trials span obesity with and without diabetes, sleep apnoea, osteoarthritis and combinations with tirzepatide and other incretins. CagriSema faces head-to-head comparisons with semaglutide and tirzepatide, renal and cardiovascular outcome studies, paediatric programmes, and even a trial in painful diabetic peripheral neuropathy. The authors of the review caution that no data yet exist on hard vascular complications, metabolic liver disease or sleep apnoea outcomes, and that evidence in type 1 diabetes remains minimal. Still, the convergence is unmistakable: three chemically distinct approaches to amylin signalling, each delivering double-digit weight loss, profound glycaemic benefits, blood pressure reductions of up to 10 mmHg, and in the case of CagriSema, the tantalising possibility of putting early type 2 diabetes into remission with a weekly injection. If the ongoing phase 3 programmes validate these findings, the amylin era of metabolic medicine may have only just begun.

Subject of Research: Amylin-based receptor agonists for the treatment of obesity and type 2 diabetes mellitus

Article Title: New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus

Article References: New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus. (n.d.). https://doi.org/10.1007/s13300-026-01921-0

Image Credits: AI Generated

DOI: 10.1007/s13300-026-01921-0

Keywords: amylin, zenagamtide, amycretin, eloralintide, CagriSema, cagrilintide, semaglutide, obesity, type 2 diabetes, GLP-1 receptor agonists, weight loss, diabetes remission